Affymax (AFFY) Sees IPO Price of $22-$24
Up)
In an amended S-1 filing, Affymax, Inc. (Nasdaq: AFFY) indicated it sees an IPO price of $22-$24 per share on 3.5 million shares. The company plans to list on the Nasdaq under the symbol "AFFY."
The offering is being made through an underwriting syndicate including Morgan Stanley, Cowen & Co, Thomas Weisel and RBC Capital.
Affymax is a biopharmaceutical company creating novel peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The company's lead product candidate, Hematide, is designed to treat anemia associated with chronic kidney disease and cancer. Anemia is a serious condition in which blood is deficient in red blood cells and hemoglobin.
The offering is being made through an underwriting syndicate including Morgan Stanley, Cowen & Co, Thomas Weisel and RBC Capital.
Affymax is a biopharmaceutical company creating novel peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The company's lead product candidate, Hematide, is designed to treat anemia associated with chronic kidney disease and cancer. Anemia is a serious condition in which blood is deficient in red blood cells and hemoglobin.
You May Also Be Interested In
- Streetinsider.com's Hot Lunchtime Reads 05/21: (AAPL) (FB) (LVS) (AFFY) (GDP)
- Morgan Stanley (MS) Drastically Lifts Client Cap on Facebook (FB) IPO Shares Ahead of Debut
- Analyst Sees Affymax's (AFFY) Omontys as Comparable to Amgen's (AMGN) Epogen; Raises AFFY Target to $21
Create E-mail Alert Related Categories
IPOsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
